Ticker Details
Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
IPO Date:	June 11, 2015
Sector:	Industrials
Industry:	Aerospace and Defense
Market Cap:	$39.18B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$3.99 | 2.70%
Avg Daily Range (30 D):	$12.72 | 3.02%
Avg Daily Range (90 D):	$14.71 | 3.27%

Institutional Daily Volume
Avg Daily Volume:	.63M
Avg Daily Volume (30 D):	1.08M
Avg Daily Volume (90 D):	1.02M

Trade Size
Avg Trade Size (Sh.):	61
Avg Trade Size (Sh.) (30 D):	22
Avg Trade Size (Sh.) (90 D):	22

Institutional Trades
Total Institutional Trades:	3,696
Avg Institutional Trade:	$17.11M
Avg Institutional Trade (30 D):	$27.74M
Avg Institutional Trade (90 D):	$28.2M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$30.44M
Avg Closing Trade (30 D):	$61.68M
Avg Closing Trade (90 D):	$58.75M
Avg Closing Volume:	89.29K

News

Jun 4, 2026 @ 6:17 PM SaaS Stocks Just Took Off. Is It Time to Chase the... Source: Neil Rozenbaum

May 28, 2026 @ 4:58 PM S&P 500 Hits Record Highs, Snowflake Jumps 37% On ... Source: Piero Cingari

May 18, 2026 @ 1:30 PM I'm Buying the Stocks Everyone Else Is Selling Rig... Source: Neil Rozenbaum

May 14, 2026 @ 2:30 PM Axon Surged After Earnings and Is Still Down Over ... Source: Leo Miller

May 6, 2026 @ 8:49 PM Axon Shares Slip Despite Q1 Results Above Expectat... Source: Erica Kollmann

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$2.57	$2.11	$.03
Diluted EPS	$2.49	$2.05	$.03
Revenue	$2.98B	$807.35M	$796.72M
Gross Profit	$1.77B	$477.29M	$461.3M
Net Income / Loss	$205.99M	$169.31M	$2.75M
Operating Income / Loss	$-24.04M	$29.24M	$-50.12M
Cost of Revenue	$1.21B	$330.06M	$335.43M
Net Cash Flow	$-633.6M	$-742.24M	$-222.75M
PE Ratio

Splits
Sep 28, 2007	1:600
Nov 30, 2004	2:1
Apr 30, 2004	2:1
Feb 11, 2004	3:1